Shutting down cancer’s
most commonly mutated pathway—
to transform the
lives of millions

Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide. Our promising pipeline targets the RAS/MAPK pathway at virtually every turn, endowing us with the potential to make a transformative difference in the treatment and lives of people suffering from a wide range of devastating cancers—bringing hope, where there was little, that the future can be brighter and cancer free.

Targeting theRAS/MAPK Pathway

Focused on cancer’s most commonly mutated pathway—affecting approximately 5.5 million lives globally per year

Advancing aRobust Pipeline

A modality-agnostic portfolio of therapeutic programs purposefully built to comprehensively shut down the RAS/MAPK pathway

READY TO STARTYour Journey?

Join a mission-driven company that believes serious cancer-fighting science can also be serious fun

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.